Investorideas.com newswire, breaking biotechnology and pharma news

Thursday, April 25, 2019

Breaking #Healthcare #Tech News - NXT-ID (NASDAQ: $NXTD) Subsidiary LogicMark Expands Retail Distribution of its Personal Emergency Response Systems


Breaking #Healthcare #Tech News - NXT-ID (NASDAQ: $NXTD) Subsidiary LogicMark Expands Retail Distribution of its Personal Emergency Response Systems 

Company adds Notifi911 to BestBuy.com and increases products available on Walmart.com (NYSE: $WMT)



SEBASTIAN, Florida, April 25, 2019 (Investorideas.com Newswire) LogicMark, LLC, a wholly owned subsidiary of NXT-ID, Inc. (NASDAQ: NXTD), today announced that Notifi911, the company’s newest Mobile Emergency Response pendant, is now available on BestBuy.com. The wearable pendant connects users to 911 at the touch of a button, allowing them to speak directly to a 911 operator anywhere cellular service is available without a monthly fee or annual contract. Notifi911 provides a direct emergency medical alert line to 911 operators, giving users the peace of mind of knowing they can call for emergency assistance when they need it. 

In addition to launching the sale of Notifi911 on BestBuy.com, LogicMark also increased the retail distribution of its personal emergency response systems by adding its Freedom Alert product to Walmart.com, expanding its offerings on that major on-line marketplace.  
  

“The addition of BestBuy.com further expands our direct-to-consumer retail strategy within the fast growing PERS market,” said Stanley Washington chief revenue officer and president healthcare for NXT-ID, Inc. “We are seeing strong demand from consumers who want a choice and the comfort of reaching emergency assistance without the financial burden of a monthly fee and annual contract.”

Notifi911 is a self-contained unit that does not require a base station, landline or cellular plan. There is no annual contract, no monthly charges and no monitoring fees to use the device, which offers a distinct value proposition and disruption over other monitored devices currently on the market by providing consumers with a product at less than 10 percent of the cost over the lifetime use of monitored devices offered by competitors. The Notifi911 pendant is fully rechargeable with a standby time of 3 months when fully charged. The robust design of the Notifi911 allows the pendant to get wet so it can be carried and used during outdoor activities and during heavy rain. LogicMark offers a one-year limited warranty on Notifi911. It is now available on BestBuy.com and Walmart.com   (NYSE: WMT)

Nxt-ID continues to be a market leader in developing groundbreaking technology in personal emergency response, home healthcare and IoT products and applications which offer low cost solutions that improve the lives of veterans and consumers by offering greater product mobility, security, safety and data connectivity. LogicMark’s FreedomAlert personal emergency response system is also now available on Walmart.com.


LogicMark has a successful history of offering PERS devices to those aging in place and with medical conditions providing them with the ability to call 911 or to alert family and friends to an emergency with the simple touch of a button. The Company is a leading provider of medical alert systems that offer this emergency service without a monthly fee or annual contract. LogicMark offers both monitored and non-monitored PERS devices.. LogicMark is currently the major provider of PERS to the United States Department of Veterans Affairs (VA) through direct relationships with individual VA hospitals. 

About NXT- ID, Inc.
NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers' mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures.  

NXT-ID includes mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems ("PERS") sold through dealers/distributors and the United States Department of Veterans Affairs and Fit Pay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem. Learn more about NXT-ID at www.nxt-id.comFitPay and the FitPay Payment Platform are the sole property of Fit Pay, Inc. For NXT-ID Inc. corporate information contact: info@nxt-id.com

Forward-Looking Statements for Nxt-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Media Contacts:
Chris Orlando
+1-760-468-7273

D. Van Zant
+1-800-665-0411


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: NXTD is a paid news, social media and PR client on Investorideas.com More info https://www.investorideas.com/About/News/Clientspecifics.asp
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

NXT-ID, Inc. (NASDAQ:NXTD)

is a Featured tech company on Investorideas.com





Get more tech stocks investor ideas - news, articles, podcasts and stock directories



Tuesday, April 23, 2019

#Healthcare #Technology Seeks to Address Aging Population Needs (ASX: COH.AX) (OTCQB: $INND) (OTC: $GNBT) (NASDAQ: $ONVO)


#Healthcare #Technology Seeks to Address Aging Population Needs (ASX: COH.AX) (OTCQB: $INND) (OTC: $GNBT) (NASDAQ: $ONVO)



Point Roberts WA, Delta BC –April 23, 2019 - Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at how the growing global aging population is inciting the health-tech industry to create innovative solutions to address growing concerns affecting this demographic, whether through hearing aids, oral aids or CBD oil.

According to Acumen Research and Consulting, the global Ear-Nose-Throat (ENT) devices market is forecast to grow at a stable CAGR around 8% during the period 2018 to 2026. In the report named “Ear-Nose-Throat (ENT) Devices Market” - Global Industry Analysis, Growth, Share, Size, Trends and Forecast, 2018-2026”, rising incorporation of advanced technology, growing awareness about various health related issues, ever-increasing healthcare costs, favorable regulatory backdrop for ENT devices, increasing geriatric population, technological advancements, user-friendly ENT devices changing lifestyle patterns and ease of availability of various ear-nose-throat devices are some of the key factors that are fuelling the ear-nose-throat devices market growth across the globe.

Read this in full at

This was reaffirmed in the The State of Hearing Report conducted for Cochlear Limited (ASX: COH), which revealed that many people know that adults with hearing loss are facing social isolation, declining self-esteem and losing the ability to communicate as their families feel the strain and that a solution could start by people simply changing how they think about hearing loss and recognizing it can often be preventable and treatable.


InnerScope Hearing Technologies Inc. (OTCQB: INND), a manufacturer and Direct-to-Consumer distributor/retailer of FDA-Registered Hearing Aids, Personal Sound Amplifier Products, Hearing Related Treatment Therapies, Doctor-Formulated Dietary Hearing Supplements and proprietary CBD Oil, recently announced that it has entered into an Agreement with AsSeenOnTV.pro to produce Direct Response TV and Brand Response TV commercials promoting its Self-Fitting Hearing Aids (“NEXUS”), Dietary Hearing Supplements “Nutrition for the Ears” and CBD Oil. The Hearing Product Commercials will feature Kevin Harrington, the pioneer of the ‘As Seen On TV’ empire and an original “Shark” from the Emmy award-winning TV reality show, Shark Tank. Kevin Harrington is also the Co-Executive Producer and the mastermind behind AsSeenOnTV.pro DRTV/BRTV campaigns.

Mr. Harrington commented “Having known and worked with the founders of InnerScope in the past, I know their passion and expertise in helping the tens of millions of people that have hearing related problems.  With 48 million people in the US alone that have reported having hearing issues, InnerScope’s Hearing Aids and Hearing Health Products have mass-market appeal. This is one of the reasons my team thinks InnerScope is a good fit to create an Omni-Channel TV/Video Media Campaign to target those tens of millions potential customers.”

Generex Biotechnology Corporation (OTC: GNBT), who, through its subsidiaries engages in the administration of formulations of large molecule drugs to the oral cavity,  recently announced that the company’s subsidiary Olaregen Therapeutix participated as a sponsor of the prestigious Diabetic Limb Salvage Conference in Washington, DC as part of its continued commitment to Wound Care Education. The Conference was attended by 600 influential experts and healthcare providers involved in the research and management of wounds, with specific emphasis on diabetic foot ulcers (DFUs). Olaregen hosted an exhibit to present information on its now commercial wound care product, Excellagen®, formulated fibrillar collagen (2.6%) wound conforming matrix, indicated for the management of several wound types, significant among them, DFUs.

Organovo Holdings, Inc. (NASDAQ: ONVO), a biotechnology company pioneering the development of 3D bio-printed tissues aimed at treating a range of serious adult and pediatric liver diseases, announced that Chief Medical Officer, Dr. Steven G. Hughes is scheduled to speak at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.

This event, modeled after The Alliance for Regenerative Medicine’s (“ARM”) highly successful Cell & Gene Meeting on the Mesa held annually in La Jolla, California, is expected to attract more than 250 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech representatives, institutional investors, academic research institutions, patient foundations, disease philanthropies and members of the life science media community.

This “new age trend” of focusing on awareness and access with regards to healthcare technology for this expanding, aging population is proving to be a valued component for the industry. It’s now “good business” to care for our elders.

For investors following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical technology stocks

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Follow us on Social Media
Follow us on Twitter https://twitter.com/Investorideas


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this news article featuring  InnerScope Hearing Technologies  is a paid for service on Investorideas.com(third party)  
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com
800-665-0411


 


Get more Biotech Investor Ideas – news, articles and stock directories 


Friday, April 12, 2019

Investor Ideas Adds New #Stocks in Cannabis, Blockchain, AI & Tech, Biotech - (CSE: $VIBE.C) (CSE: $PBIT.C) (NASDAQ: $TW) (NASDAQ: $SSTI)

Investor Ideas Adds New #Stocks in Cannabis, Blockchain, AI & Tech, Biotech - (CSE: $VIBE.C) (CSE: $PBIT.C) (NASDAQ: $TW) (NASDAQ: $SSTI)

Point Roberts, WA, Delta BC – April 12, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in cannabis, blockchain, AI, tech and biotech.


New companies include an integrated cannabis firm looking to become a multi-state operator and a blockchain company that overlaps into cannabis with cash-only blockchain-enabled payment processing and point-of-sale systems.

The latest tech companies are the fintech company, Tradeweb Markets Inc. (NasdaqGS:TW) offering advanced trading solutions and the AI company, ShotSpotter, Inc. (NasdaqCM: SSTI) which uses AI to provide precision-policing solutions for law enforcement to help deter gun violence.

The newest biotech company is also Nasdaq-listed and has several late-stage clinical assets targeting psychiatric and movement disorders.




New Cannabis Companies:
Vibe Bioscience Ltd. (CSE:VIBE) is a vertically integrated cannabis company whose mission is to become an industry leading multi-state operator within the United States. The Company delivers exceptional retail experiences with its brand and ethos, premier cultivation product, and technology enabled delivery and distribution. Vibe’s management team brings deep experience in retail, cannabis cultivation, and mergers and acquisitions to support its U.S. expansion through accretive acquisitions and organic growth.

New Blockchain Companies:
POSaBIT Systems Corporation (CSE: PBIT) is a financial technology company that delivers unique and innovative, blockchain-enabled payment processing and point-of-sale systems for cash-only businesses. POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly and utilizes top-of-the-line hardware. POSaBIT’s unique solution provides a safer and transparent environment for merchants while creating a better overall experience for the consumer.

New Tech Companies:
Tradeweb Markets Inc. (NasdaqGS:TW) offers institutional, wholesale and retail market participants deep pools of liquidity, advanced technology and a broad range of data solutions that are designed to deliver better price discovery, order execution and trade workflows. More than 2,500 clients connect to Tradeweb to form a global network of the world’s leading global asset managers, hedge funds, insurance companies, central banks, banks and dealers, proprietary trading firms and retail brokerage and financial advisory firms, as well as regional dealers. Tradeweb offers advanced trading solutions for over 40 products in more than 60 countries across the globe, including government bonds, mortgage securities, municipal bonds, corporate bonds, derivatives, and ETFs

ShotSpotter, Inc. (NasdaqCM:SSTI) provides precision-policing solutions for law enforcement to help deter gun violence and make cities, campuses and facilities safer. The company’s flagship product, ShotSpotter® Flex™, is the leading gunshot detection, location and forensic analysis system, and is trusted by more than 90 cities.  ShotSpotter® Missions™ (formerly HunchLab) uses artificial intelligence-driven analysis to help strategically plan patrol missions and tactics for maximum crime deterrence. ShotSpotter has been designated a Great Places to Work® company.

New Biotech Companies:
Seelos Therapeutics, Inc. (NASDAQCM: SEEL) is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411












Wednesday, March 27, 2019

#Biotech Stock News: Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)


#Biotech Stock News: Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)


Point Roberts, WA, Delta BC - March 27, 2019 - Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance.

GELifesciences.com, talking about the Antibody boom says; “Many small and start-up companies are developing new ideas as to how antibodies can be used. In many cases, these companies will go on to be acquired by larger companies with the financial capability to progress their ideas further. But with costs to establish manufacturing capability in suitable existing buildings at not much more than $10-15 M, this strategic opportunity lies within reach even for smaller businesses. Despite steep competition and the need for significant investment, the antibody space is a lucrative opportunity with various therapeutic avenues that can be explored.”

Looking at some companies in the sector, Immunoprecise Antibodies Ltd. (TSXV: IPA) (OTC: IPATF), a therapeutic antibody discovery company, recently received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute (NCI). Under the subcontract, IPA will discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.

The rabbit monoclonal antibodies discovered and produced under this subcontract will be used in the key applications of immunohistochemistry and immuno-Multiple Reaction Monitoring (immuno-MRM). The antibodies will be generated for NCI’s Antibody Characterization Program.

Immuno-MRM is a leading-edge targeted mass spectrometry technique that relies on antibodies to enrich peptides from complex biological samples that are then quantified by mass spectrometry. Rabbit monoclonal antibodies are highly sought after for this purpose because they exhibit high specificity and bind their target with high affinity. Immuno-MRM is being used to discover novel biomarkers and develop a new generation of clinical diagnostic tests that could lead to improved cancer detection, diagnosis, and treatment.


Zymeworks Inc. (NYSE: ZYME) (TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics reported in January the achievement of a new development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for an immuno-oncology bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform.
Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of cancer recently reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase 3 registration trial, the VISTA Trial, of Vicinium® for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) and deemed BCG-unresponsive. The data reported show clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and twelve months of follow-up in the trial consistent with the data in the completed Phase 1 and Phase 2 clinical trials. Importantly, Vicinium continues to be generally well-tolerated in treated patients.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTC: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases will soon present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease.  ProMIS Neurosciences' Chief Scientific Officer, Dr. Neil Cashman will discuss the preclinical data at a podium presentation on March 31 as well as co-moderate the March 30 panel discussion on disease mechanisms in Alzheimer's disease and Parkinson's disease.

ResearchandMarkets, in a biopharma market overview reported, “The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%.”

Within the related segments, Monoclonal Antibodies are expected to gain the largest market size.

For investors following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical technology stocks

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI

Follow us on Social Media
Follow us on Twitter https://twitter.com/Investorideas


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring  (TSX VENTURE: IPA) (OTC PINK: IPATF)  a paid for service on Investorideas.com(third party)  . Learn more about costs and our  services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411